AKRO [NASD]
Akero Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.15 Insider Own1.30% Shs Outstand46.42M Perf Week32.61%
Market Cap1.56B Forward P/E- EPS next Y-3.56 Insider Trans-28.45% Shs Float41.69M Perf Month186.75%
Income-110.20M PEG- EPS next Q-0.82 Inst Own80.50% Short Float13.12% Perf Quarter230.54%
Sales- P/S- EPS this Y-14.90% Inst Trans5.10% Short Ratio4.08 Perf Half Y156.43%
Book/sh4.19 P/B9.14 EPS next Y-14.50% ROA-56.90% Target Price44.50 Perf Year77.86%
Cash/sh4.45 P/C8.61 EPS next 5Y-14.60% ROE-66.50% 52W Range7.52 - 38.51 Perf YTD81.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.52% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low409.44% ATR2.58
Employees37 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)82.97 Volatility10.94% 10.23%
OptionableYes Debt/Eq0.06 EPS Q/Q6.80% Profit Margin- Rel Volume0.80 Prev Close38.46
ShortableYes LT Debt/Eq0.06 EarningsAug 04 BMO Payout- Avg Volume1.34M Price38.31
Recom1.80 SMA2050.84% SMA50118.98% SMA200155.61% Volume1,072,269 Change-0.39%
Sep-14-22Upgrade Evercore ISI In-line → Outperform $10 → $50
Oct-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $27
Sep-10-21Initiated BofA Securities Buy $40
Feb-26-21Initiated Guggenheim Buy $54
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-01-20Reiterated H.C. Wainwright Buy $33 → $45
Mar-02-20Initiated H.C. Wainwright Buy $33
Feb-10-20Initiated Canaccord Genuity Buy $36
Jul-15-19Initiated ROTH Capital Buy $34
Jul-15-19Initiated JP Morgan Overweight $28
Jul-15-19Initiated Jefferies Buy $28
Jul-15-19Initiated Evercore ISI Outperform $35
Oct-05-22 09:40AM
Sep-23-22 06:35PM
Sep-19-22 04:01PM
Sep-14-22 08:07PM
04:35PM
02:50PM Loading…
02:50PM
01:35PM
10:27AM
Sep-13-22 04:31PM
04:01PM
11:05AM
11:04AM
09:10AM
08:27AM
07:49AM
06:00AM Loading…
06:00AM
Sep-08-22 04:01PM
Aug-25-22 11:53AM
Aug-24-22 10:28AM
08:00AM
Aug-04-22 04:05PM
Jun-27-22 07:00AM
Jun-16-22 09:22AM
07:00AM
Jun-13-22 08:00AM
Jun-01-22 04:05PM
May-06-22 07:00AM
May-02-22 07:30AM
Mar-07-22 04:13AM
Feb-25-22 07:00AM
08:00AM Loading…
Feb-08-22 08:00AM
Jan-14-22 09:40AM
Jan-04-22 04:05PM
Nov-26-21 05:28PM
Nov-17-21 10:07AM
Nov-12-21 08:01AM
07:00AM
Nov-09-21 04:15PM
Oct-20-21 10:03AM
Oct-19-21 04:15PM
Oct-05-21 08:00AM
Sep-08-21 06:21AM
Sep-07-21 08:00AM
Aug-13-21 07:00AM
Jul-14-21 08:00AM
Jul-08-21 01:24PM
11:10AM
Jun-25-21 11:30AM
Jun-21-21 11:33AM
08:00AM
Jun-09-21 10:03AM
09:06AM
Jun-01-21 08:00AM
May-28-21 04:05PM
10:09AM
May-13-21 07:00AM
Apr-26-21 08:00AM
Mar-23-21 08:00AM
Mar-22-21 04:01PM
06:30AM
Mar-16-21 08:00AM
Mar-11-21 11:40PM
Feb-24-21 08:30AM
Feb-23-21 04:05PM
Jan-04-21 04:05PM
Dec-12-20 10:07PM
Nov-24-20 04:05PM
Nov-13-20 08:00AM
Nov-12-20 04:05PM
Oct-21-20 04:05PM
Oct-19-20 10:13AM
Oct-16-20 07:30AM
Oct-02-20 07:30AM
Sep-30-20 08:00AM
Sep-28-20 04:05PM
Sep-24-20 07:30AM
Sep-16-20 04:25PM
Sep-13-20 08:48AM
Sep-09-20 04:05PM
Aug-12-20 04:05PM
Jul-23-20 11:02AM
Jul-21-20 11:00AM
Jul-10-20 04:05PM
Jul-07-20 08:15PM
Jul-06-20 07:00AM
Jul-02-20 08:21AM
Jul-01-20 09:03AM
08:12AM
Jun-30-20 04:05PM
Jun-29-20 04:05PM
Jun-27-20 09:28PM
Jun-17-20 08:00AM
Jun-10-20 12:00PM
11:30AM
10:30AM
08:00AM
Jun-04-20 07:08AM
May-27-20 09:24AM
May-26-20 04:05PM
May-22-20 11:30AM
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cheng AndrewPresident & CEOOct 03Option Exercise0.6110,0006,150320,148Oct 05 08:55 AM
Cheng AndrewPresident & CEOOct 03Sale33.2310,000332,278310,148Oct 05 08:55 AM
Rolph TimothyChief Scientific OfficerSep 30Option Exercise16.4320,000328,589243,837Oct 04 08:57 PM
Rolph TimothyChief Scientific OfficerSep 30Sale32.7245,0001,472,400198,837Oct 04 08:57 PM
White William RichardChief Financial OfficerSep 13Option Exercise7.0132,500227,79236,929Sep 15 07:57 PM
Cheng AndrewPresident & CEOSep 13Option Exercise0.6160,00036,900370,148Sep 15 07:59 PM
Yale CatrionaChief Development OfficerSep 13Sale27.4840,0001,099,22882,073Sep 15 07:59 PM
White William RichardChief Financial OfficerSep 13Sale27.0332,500878,3414,429Sep 15 07:57 PM
Rolph TimothyChief Scientific OfficerSep 13Sale29.1822,500656,550223,837Sep 15 07:56 PM
Cheng AndrewPresident & CEOSep 13Sale27.4260,0001,645,444310,148Sep 15 07:59 PM
Cheng AndrewPresident & CEOMar 01Option Exercise0.6110,0006,150318,996Mar 02 08:40 PM
Cheng AndrewPresident & CEOMar 01Sale17.5910,000175,900308,996Mar 02 08:40 PM
Cheng AndrewPresident & CEOFeb 01Option Exercise0.6110,0006,150318,996Feb 03 07:12 PM
Cheng AndrewPresident & CEOFeb 01Sale17.5610,000175,600308,996Feb 03 07:12 PM
White William RichardChief Financial OfficerJan 14Option Exercise7.019,70067,98712,977Jan 18 09:48 PM
White William RichardChief Financial OfficerJan 14Sale22.039,700213,6913,277Jan 18 09:48 PM
Cheng AndrewPresident & CEOJan 10Option Exercise0.6110,0006,150308,996Jan 11 09:40 PM
Young JonathanChief Operating OfficerJan 07Option Exercise0.6127,74417,063163,254Jan 11 04:40 PM
Cheng AndrewPresident & CEOJan 03Option Exercise0.6153,00032,595308,996Jan 04 09:21 PM
White William RichardChief Financial OfficerDec 21Option Exercise7.011007013,377Dec 23 09:03 PM
White William RichardChief Financial OfficerDec 21Sale22.001002,2003,277Dec 23 09:03 PM
White William RichardChief Financial OfficerDec 17Option Exercise7.013,20022,4296,477Dec 20 04:54 PM
White William RichardChief Financial OfficerDec 17Sale22.043,20070,5283,277Dec 20 04:54 PM
Cheng AndrewPresident & CEODec 02Sale20.1817,500353,150255,996Dec 03 05:20 PM
Young JonathanChief Operating OfficerNov 04Sale24.336,220151,333135,510Nov 05 04:17 PM
Young JonathanChief Operating OfficerNov 03Sale24.2718,780455,791141,730Nov 05 04:17 PM
Cheng AndrewPresident & CEONov 02Sale22.5717,500394,975273,496Nov 03 04:16 PM
White William RichardChief Financial OfficerNov 01Option Exercise7.016,50045,5589,777Nov 03 04:15 PM
White William RichardChief Financial OfficerNov 01Sale22.246,500144,5603,277Nov 03 04:15 PM
Yale CatrionaChief Development OfficerOct 15Sale21.5912,500269,826120,921Oct 18 04:21 PM